1. Biocon may sell 11% in Syngene IPO

Biocon may sell 11% in Syngene IPO

Biocon on Tuesday said it would sell up to 11% in its contract research arm Syngene in the upcoming IPO.

By: | Bangalore | Published: April 29, 2015 2:46 AM

Biocon on Tuesday said it would sell up to 11% in its contract research arm Syngene in the upcoming IPO.

“We are unlocking value from Syngene to fund our R&D programmes, which include a rich pipeline of biosimilars and novel biologics. This fund infusion will help accelerate these programmes which are at various stages of development currently,” said Kiran Mazumdar-Shaw, chairman and MD, Biocon.

For Updates Check Company News; follow us on Facebook and Twitter

Calculate your income tax post budget 2018 through this Income Tax Calculator, get latest news on Budget 2018 and Auto Expo 2018. Like us on Facebook and follow us on Twitter.

Tags: BioconIPO
  1. No Comments.

Go to Top